Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketplace In Brief

Executive Summary

CFSAN on nanotech: FDA's Center for Food Safety and Applied Nutrition continues to seek information from industry on nanotechnology in products including cosmetics and dietary supplements, and has no plans for now to move forward with separate regulations or a definition for products derived through nano-engineering, senior FDA staff including Office of Cosmetics and Colors Director Linda Katz reported in February during the Food and Drug Law Institute's annual meeting in Washington D.C. Regulation will continue to be driven by statutory classification, the center added, noting it has no plans to update the 2007 Nanotechnology Task Force Report. The House passed H.R. 554 on Feb. 11 in an effort to direct federal nanotech research, strengthen public-private partnerships and prioritize public health and safety (1"The Rose Sheet" Feb. 16, 2009, In Brief)
Advertisement

Related Content

Nanotech bill sails through House
Advertisement
UsernamePublicRestriction

Register

RS015993

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel